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ARTICLE
Nano-enabled pancreas cancer immunotherapy
using immunogenic cell death and reversing
immunosuppression
Jianqin Lu 1,2,3, Xiangsheng Liu1,3, Yu-Pei Liao1, Felix Salazar4, Bingbing Sun 1, Wen Jiang 2,
Chong Hyun Chang2,3, Jinhong Jiang2, Xiang Wang2, Anna M. Wu4, Huan Meng1,2,3,5 & Andre E. Nel1,2,3,5
While chemotherapy delivery by nanocarriers has modestly improved the survival prospects
of pancreatic ductal adenocarcinoma (PDAC), additional engagement of the immune
response could be game changing. We demonstrate a nano-enabled approach for accom-
plishing robust anti-PDAC immunity in syngeneic mice through the induction of immunogenic
cell death (ICD) as well as interfering in the immunosuppressive indoleamine 2,3-dioxy-
genase (IDO) pathway. This is accomplished by conjugating the IDO inhibitor, indoximod
(IND), to a phospholipid that allows prodrug self-assembly into nanovesicles or incorporation
into a lipid bilayer that encapsulates mesoporous silica nanoparticles (MSNP). The porous
MSNP interior allows contemporaneous delivery of the ICD-inducing chemotherapeutic
agent, oxaliplatin (OX). The nanovesicles plus free OX or OX/IND-MSNP induce effective
innate and adaptive anti-PDAC immunity when used in a vaccination approach, direct tumor
injection or intravenous biodistribution to an orthotopic PDAC site. Significant tumor
reduction or eradication is accomplishable by recruiting cytotoxic T lymphocytes, con-
comitant with downregulation of Foxp3+ T cells.
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Pancreatic ductal adenocarcinoma (PDAC) is an almostuniformly fatal disease with a 5-year survival outcome ofless than 6%1. In spite of its dismal prognosis, the intro-
duction of commercial nanocarriers that deliver paclitaxel (PTX)
or irinotecan has had some survival impact2, 3. While PTX
delivery by an albumin-nanocarrier suppresses the tumor stroma
to increase gemcitabine uptake, the delivery of irinotecan by a
liposomal carrier improves pharmacokinetics (PK). Moreover,
our own studies using mesoporous silica nanoparticles (MSNP)
have shown in a robust orthotopic PDAC animal model that it is
possible to introduce smart-design features for improving irino-
tecan loading, efficacy and safety, or deliver a synergistic,
ratiometric-designed combination of PTX and gemcitabine4, 5.
In addition to improved tumor cell killing, we envisage the use
of nanocarriers to deliver chemotherapy in support of PDAC
immunotherapy. One possible approach is to use chemotherapy
to induce immunogenic cell death (ICD). Doxorubicin (DOX) is
the classical example of inducing an ICD response, which is
characterized by apoptotic cell death, accompanied by the
expression of calreticulin (CRT) on dying tumor cell surfaces6.
CRT provides an “eat-me” signal for dendritic cell (DC) uptake6,
7. The subsequent release of ATP and a non-histone chromatin
protein, high-mobility group box 1 (HMGB-1), from the tumor
cells provide adjuvant stimuli to the antigen presenting DC7. This
cell biological sequence is dependent on the ability of select
chemotherapeutic agents, physical stimuli (e.g., irradiation) and
cytotoxic viruses to trigger a combination of apoptotic cell death,
endoplasmic reticulum stress and autophagy8–12.
Oxaliplatin (OX), one of the four components in the FOL-
FIRINOX chemotherapy regimen used in PDAC, can also induce
an ICD response in various cancer cells, including pancreatic
cancer cells13. We hypothesized that encapsulated OX delivery to
the PDAC site may allow us to induce a regional ICD effect. We
also posited that the immunogenic effects of OX could be
enhanced if we reverse the immunosuppressive effects of the
regionally overexpressed metabolic enzyme, indoleamine 2,3-
dioxygenase 1 (IDO1), at the PDAC site. IDO1 controls an
immune surveillance pathway in the tumor microenvironment
(TME) by catalyzing a rate-limiting step in the kynurenine
pathway14–17. By converting L-tryptophan (Trp) to L-kynurenine
(Kyn), IDO1 restricts Trp availability in tumor cells and innate
immune cells; this triggers effector pathways that interfere in the
development of cytotoxic T cells, while inducing Tregs18, 19.
These immunosuppressive effects can be rescued by 1-methyl-D-
tryptophan (a.k.a. indoximod, IND)20, 21, a small molecule inhi-
bitor that is poorly retained at the tumor site22, 23. We argued that
a change in the PK of this drug could be an additional benefit of a
nano-enabled approach24. Figure 1 illustrates our conceptual
thinking of using a dual delivery system for OX plus IND to
develop an effective immunotherapy approach for PDAC, pre-
mised on an ICD stimulus plus interference in the IDO pathway.
We report the design of soft and hard nanocarrier platforms
for delivery of OX plus a lipid-conjugated IND prodrug. We
demonstrate the feasibility of achieving tumor regression or
eradication of a Kras-derived PDAC model, using a vaccination
approach, local tumor injection or systemic administration. The
employment of a nano-enabled platform was critical for
improving the PK of drug delivery, intratumoral drug con-
centrations, and duration of action. In addition to providing
immunostimulation, the IND prodrug had the unexpected benefit
of synergistically enhancing the ICD response, with boosting of
innate and adaptive anti-PDAC immunity.
Results
Oxaliplatin induces an ICD response in PDAC. ICD is a
modified form of apoptosis that can be used to initiate an effective
immune response against endogenous tumor antigens7. Although
ICD is best described for anthracycline chemotherapeutics (e.g.,
DOX), we were interested in finding a recognized PDAC drug to
provide the same stimulus. OX is FDA-approved for PDAC
treatment, and has been shown to induce ICD in PDAC cancer
cells13. We initiated a screen for CRT expression in human and
mouse PDAC cell lines, in which OX was compared with DOX
and cisplatin (Cis). KPC cells were derived from a spontaneous
PDAC tumor that developed in a transgenic KrasLSL-G12D/
+/Trp53LSL-R172H/+/Pdx-1-Cre (KPC) mouse25. While OX and
DOX treatment induced CRT expression on the surface of KPC
cells as viewed by confocal microscopy, no surface expression was
seen for Cis (Fig. 2a). More quantitative evaluation by flow
cytometry confirmed the dose- and time-dependent effects of OX
and DOX (Fig. 2b and Supplementary Fig. 1a). A similar stress
response was observed in the human PANC-1 pancreatic cancer
cell line (Supplementary Fig. 1b), as well as using an ELISA to
measure HMGB-1 release in both cell types (Supplementary
Fig. 1c).
The gold standard for confirming ICD in vivo is a vaccination
response in a syngeneic animal model7. KPC cells can be grown
subcutaneously (SC) to tumors in immune competent B6/129
mice. To allow bioluminescence imaging of the tumor site, KPC
cells were transfected with a luciferase vector4. We asked whether
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Fig. 1 Schematic to illustrate how dual delivery of OX and IND may impact
the anti-PDAC immune response. We hypothesized that nano-enabled co-
delivery of a chemotherapeutic agent, which provides an ICD stimulus, and
IND, which interferes in the IDO pathway, may combine to trigger a robust
PDAC immune response. OX (#1) induces an ICD response (#2) in which
CRT expression on the dying tumor cell surfaces provides an “eat-me”
signal for DC uptake, as well as the release of HMGB-1 and ATP that deliver
adjuvant stimuli to DC (#3). Following uptake of the dying tumor cells by
DC, their maturation and cross-presentation of endogenous tumor-
associated antigens (TAAs) (#4), the recruitment and activation of CD8+
T cells (#5) will lead to granulysin and perforin mediated killing of primary
(#6) and metastatic cancer cells (#7). The concomitant delivery of IND-PL
(#8) interferes in the IDO metabolic pathway, which can lead to
strengthening the ICD effect by interfering in Treg development and
overcome other immunomodulatory effects (#9). The ICD pathway also
allows the activation of helper and memory T cells, which prevent disease
recurrence (#10). Following proof-of-prinipal testing of this scheme, we
also discovered that IND syngergistically enhances the ICD effect, providing
more than just an additive outcome (#11)
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ex vivo exposure of KPC cells to above chemo agents can induce
an adequate immune response to prevent KPC growth SC.
Suspensions of dying tumor cells, generated by exposure to OX
(50 µM), DOX (1 µM), or Cis (100 µM) for 24 h, were SC injected
on 2 occasions (7 days apart) in one flank of the animals. The
animals was subsequently challenged by SC injection of live KPC
cells on the contralateral flank, 7 days later (Fig. 2c). While
vaccination with OX- or DOX-treated cells significantly sup-
pressed tumor growth on the contralateral side, Cis treatment had
no effect (Fig. 2d). The magnitude of the growth inhibition was
confirmed by IVIS imaging (Supplementary Fig. 2a). Notably, 3
(out of 7) mice in the OX-treated group and 2 (out of 7) mice in
DOX-treated group survived tumor-free. The rest of the animals
were killed on day 29 for immunohistochemistry (IHC) and flow
cytometry analysis.
IHC revealed increased tumor staining for CD8+ T cells in
parallel with a decreased regulatory (Foxp3+) T cell component in
animals vaccinated with OX or DOX-treated cells (Fig. 2e). Cis
treatment had no effect. Quantitative assessment of the same
biomarkers using flow cytometry and single-cell suspensions,
demonstrated 5.1- and 5-fold increase in the CD8+/Tregs cell
ratios in the OX and DOX vaccinated groups, respectively,
compared to saline (Fig. 2e, right panel). Since elevation of the
CD8+/Tregs ratio is compatible with a cytotoxic response, IHC
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Fig. 2 Oxaliplatin-induced ICD provides a successful anti-PDAC vaccination approach. a Confocal microscopy showing the induction of the ICD marker,
CRT, in KPC cells in the presence of PBS, Cis (100 µM), OX (50 µM), and DOX (1 µM) for 4 h. The cell nuclei, surface membrane and CRT were detected
by Hoechst 33342, Alexa Fluor® 488-Conjugated Wheat Germ Agglutinin, and Alexa Fluor® 647-conjugated anti-CRT antibody staining, respectively. Scale
bar is 20 μm. b CRT surface detection by flow cytometry, using the same conditions and reagents as in a (3 independent experiments). c Animal
experimentation using 2 rounds of vaccination one week apart, followed by injecting live KPC cells SC on the contralateral side. The details of the animal
vaccination experiment are provided in the methods section. Tumors were collected on day 29 for IHC and flow cytometry analysis. d Spaghetti curves to
show KPC tumor growth in the contralateral flank. e Tumor collection was performed after euthanizing the animal to conduct IHC. Representative images
are shown for the IHC staining of CD8 (upper panel) and Foxp3 (lower panel) T cells. The tumor tissues were also analyzed by flow cytometry to
determine the CD8/Tregs ratio (see experimental section for details) (right panel). f IHC staining for cleaved caspase-3 (CC-3) and IFN-γ to demonstrate
recruitment of cytotoxic T cells in response to ICD. Scale bar in IHC is 100 μm. g The 3 surviving animals in the OX-treated group, described in c, received
orthotopic implant of live KPC cells on day 74. Animals maintained their tumor-free status up to 132 days, whereupon they were euthanized for collecting
the immune splenocytes to perform an adoptive transfer experiment. IV injection of the immune splenocytes into the tail vein of B6/129 mice prevented
the growth of KPC cells, implanted SC. The controls included IV administration of non-immune splenocytes or saline. The same experiment was also
carried out in mice receiving SC injection of B16 melanoma cells. In this case, there was no interference in tumor growth by immune splenocytes,
demonstrating the antigen specificity of the adoptive transfer response (Supplementary Fig. 3). The results are expressed as mean± SEM. *p< 0.05; **p<
0.01, (ANOVA)
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staining was used to confirm the appearance of activated
(cleaved) caspase-3 (CC-3) and IFN-γ (Fig. 2f) at the tumor sites
of animals vaccinated with OX or DOX-treated cells.
The three surviving animals in the OX-induced ICD group were
used for orthotopic implantation of KPC cells in the pancreas on
day 74. No orthotopic tumors emerged up to day 132, compared
to fatality in non-vaccinated animals within 30 days. The
surviving, prior vaccinated and orthotopic-challenged animals,
were euthanized on day 132 to collect splenocyte populations for
adoptive transfer to non-immune animals. The splenocytes were
intravenously (IV) injected into the tail vein of 12 non-immunized
B6/129 mice. The control was a group of 12 animals receiving IV
injection of splenocytes collected from non-immune animals or
animals treated with saline only. Each of the three groups was
divided in half, with 6 animals receiving SC injection of live KPC
cells and the rest being injected with B16 melanoma cells.
Monitoring of tumor growth demonstrated a significant reduction
in KPC growth in animals injected with immune splenocytes,
compared to animals receiving non-immune splenocytes or saline
only (Fig. 2g). Two of the six mice receiving immune splenocytes
survived tumor-free. No impact was seen on B16 tumor growth
(Supplementary Fig. 3). These results indicate that OX treatment
generates an ICD effect that culminates in a memory T cell
response for PDAC. An abbreviation list was provided for the ease
of reading (Supplementray Table 1).
Synthesis of the IND prodrug for immunomodulatory therapy.
IDO1 is frequently overexpressed in the solid TME, where its
metabolic action of converting Trp to Kyn can interfere in the
proliferation of cytotoxic T cells, expansion of Tregs and inter-
ference in memory T cell development18, 19. A number of small
molecule inhibitors of the IDO effector pathway have been
developed for cancer treatment, including IND20, 21. While IND is
currently being tested in several clinical trials (including PDAC),
its utility as a stand-alone immunostimulatory agent appears to be
modest and is often combined with other treatment modalities23,
24. Oral administration requires a high dose (up to 1200mg b.i.d.)
26 to compensate for its poor water solubility, rapid blood clear-
ance and limited accumulation at the tumor site27. These poten-
tially unfavorable PK in humans was corroborated by the animal
data, in which we observed that IV administration had a short
circulatory half-life (t1/2) of <0.083 h, with <0.1% of the injected
IND dose gaining access to the tumor site (Supplementary Fig. 4i).
We hypothesized that the biodistribution, retention and PK of
IND at the tumor site can be improved by a nano-enabled drug
design approach that prolongs the duration of action. An IND
prodrug was constructed by using the labile ester bond to
conjugate 1-methyl-D-Trp to a single-chain phospholipid, 1-
palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine (PL) (Fig. 3a).
The conjugation reaction was accomplished by the following
steps: (i) Boc protection of the IND amine group, (ii)
esterification of Boc-IND with the PL, and (iii) Boc removal
(Fig. 3a). The detailed synthesis and characterization are
described in Supplementary Fig. 4. When aqueously suspended,
amphiphilic IND-PL self-assembles into spherical ~80 nm
nanovesicles (IND-NVs), demonstrated by cryo-electron micro-
scopy (cryoEM) (Fig. 3b and Supplementary Fig. 4h). UPLC-MS/
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Fig. 3 Synthesis of a self-assembling indoximod (IND) prodrug for immune modulatory activity. a Detailed synthesis and characterization for generating the
phospholipid-conjugated IND prodrug (IND-PL) appears in Supplementary Fig. 4. Successful synthesis of IND-PL was confirmed by a calculated m/z of
696.4353 during ESI-MS (Supplementary Fig. 4f, g). b Illustration depicting self-assembly of IND-PL nanovesicles (IND-NV), with IND securely anchored in
the lipid bilayer. A representative cryoEM image of the spherical IND-NV, with diameter ~80 nm and lipid bilayer thickness of ~7 nm is shown as well. A
lower magnification cryoEM picture is shown in Supplementary Fig. 4h. c UPLC-MS/MS to determine the cellular uptake and release of IND-PL. KPC cells
were treated with 100 µg/mL free IND or IND-NV for the indicated incubation period, followed by collection of cells (via trypsinization) and drug
extraction. The data show the fold-increase of the intracellular drug concentration as compared to free IND. A typical UPLC-MS/MS readout is shown in
Supplementary Fig. 5. Details about the sample preparation and analysis are described in Supplementary Fig. 5. Three independent experiments were
performed. d Role of IDO in providing immune suppression in the TME by inhibiting the mTOR pathway through Trp depletion. IND rescues this
interference, acting as a highly potent Trp mimetic. This rescue leads to the phosphorylation and activation of P-S6K, as well as activation of PKC-ϴ that is
involved in signal transduction by the T-cell antigen receptor; e KPC cells were treated with free IND or IND-NV at the indicated concentrations for 3 h in
tryptophan-deficient DMEM. Western blot assays showing the enhanced effect of IND-PL on mTOR signaling, which can be conveniently studied by
assessing the phosphorylation of P-S6K (upper panel). The graphic in the right panel shows the pooled data for 3 experiments to assess P-S6K activation at
10 μM and 50 μM IND. The results are expressed as mean± SEM. *p< 0.05; **p< 0.01, (ANOVA)
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MS was used to study IND uptake and release in KPC cells
(Supplementary Fig. 5). Compared to free IND, the total
intracellular IND content increased 34.5, 43.9, and 51.9-fold
after exposure to IND-NV at 4, 24, and 72 h in cells collected by
trypsinization (Fig. 3c). Increased cellular uptake was accom-
panied by increased IND release from the prodrug (Fig. 3c). An
abiotic study confirmed that esterase activity and acidification of
the incubation medium can release the IND from the prodrug;
similar to what may happen in a mammalian cell (Supplementary
Fig. 5c).
IDO-mediated Trp depletion and Kyn accumulation leads to
the perturbation of downstream effector pathways involved in
immune suppression14, 21, 28. Key among these, is the mTOR
pathway that is sensitive to Trp depletion, resulting in
interference in the phosphorylation and activation of P-S6 kinase
(P-S6K) (Fig. 3d), as well as inhibition of autophagy17. In
accordance with the increased bioavailability of IND-PL vs. free
IND, anti-phosphopeptide immunoblotting demonstrated that
the conjugated drug is better capable of enhancing P-S6K
phosphorylation (Fig. 3e). In addition to studying S6K phosphor-
ylation, we also looked at the effect of the IDO pathway in
controlling the aryl hydrocarbon receptor (AhR) pathway that
engages the autocrine AhR-IL-6-STAT3 signaling loop, putatively
responsible for sustained IDO expression (Supplementary Fig. 6b)
28. Noteworthy, IND-NV was more potent than the free drug in
interfering in IL-6 production in KPC cells (Supplementary
Fig. 6c).
The IND prodrug synergizes with OX at the PDAC tumor site.
Because the vaccination approach does not address the immu-
nosuppressive TME in an established tumor, we asked whether
IND-PL could strengthen the OX-induced ICD response in KPC
tumors grown SC (Fig. 4). Following tumor growth to 60–80 mm3
size, the mice received a single intratumoral (IT) injection of 1.25
mg/kg OX15 plus either a low (L) (2.5 mg/kg IND) or a high (H)
(12.5 mg/kg IND) dose of IND-NV IT (Fig. 4a). Controls inclu-
ded animals receiving injection with saline, free OX (1.25 mg/kg),
free IND (12.5 mg/kg), or IND-NV (12.5 mg/kg IND) alone.
Serial assessment of tumor volume, followed by euthanizing of
animal on day 31 for in situ inspection of tumor size (Fig. 4c)
demonstrated that OX plus IND-NV (H) had the most robust
tumor reduction effect, while OX plus IND-NV (L) or OX plus
free IND (L or H) had lesser potency (Fig. 4b, c). Free IND had
a
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Fig. 4 Co-administration of IND-NV with OX at the tumor site augments anti-PDAC immunity. a Local co-administration in KPC tumors established by SC
injection in syngeneic mice. Treatment details are provided in the methods section. b KPC tumor growth curve after a single IT injection of the various
drugs at a tumor size of 60–80mm3. OX was injected at 1.25 mg/kg15. Low (L, 2.5 mg IND/kg) and High (H, 12.5 mg IND/kg) refer to the IND or IND-NV
doses. c Representative tumor images from each group after euthanizing the animal on day 31. d IHC depicting CD8 and Foxp3 biomarkers in the collected
tumor tissue. A full set of panels of the IHC staining data are shown in Supplementary Fig. 7a–j. e Flow cytometry determination of CD8/Tregs ratio, as
described in d. f Flow cytometry analysis to determine CD91 expression in the population of CD45+/CD11b+/CD11c+ cells in the tumor tissue. g IHC to
depict CRT and HMGB-1 expression in the collected tumor tissues. The results are expressed as mean± SEM. *p< 0.05; **p< 0.01, (ANOVA). The scale
bar is 100 μm
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no effect on tumor growth, while IND-NV alone exerted a small
effect (Fig. 4b, c).
The resected tumor tissues were used for IHC and multi-
parameter flow cytometry analysis. IHC staining for CD8 and
Foxp3 showed that OX plus IND-NV (H) resulted in significantly
enhanced recruitment of CD8+ T cells along with a reduction in
Foxp3+ T cells (Fig. 4d). Moreover, the comprehensive IHC
profiles shown in Supplementary Fig. 7a–k demonstrate good
responsiveness to OX alone, OX plus IND-NV (L), and OX plus
IND (H or L), although not as prominent as OX plus IND-NV
(H). These findings were corroborated by flow cytometry,
demonstrating that the co-administration of OX plus IND-NV
(H) synergistically enhance the CD8+/Tregs ratio compared to
other treatments (Fig. 4e).
Since IDO also plays a significant role in DC, we asked whether
IND co-administration could impact the innate immune events
that underpin tumor antigen presentation. In this regard, CD91
expression on DC serves as the binding receptor for CRT+ tumor
cells, while TLR4 is engaged by released HMGB-16, 7, 16, 17. Multi-
parameter flow cytometry showed that OX plus IND-NV (H)
induced the most abundant CD91 expression in a CD45+/CD11b
+/CD11c+ cell population, compared to animals treated with free
drugs (Fig. 4f). The phenotypic data were also confirmed by IHC
staining for CD91 in the tumor tissue (Supplementary Fig. 7e).
Moreover, IHC analysis of CRT and HMGB-1 expression
demonstrated more abundant expression during treatment with
OX plus IND-NV (H) (Fig. 4g). The comprehensive IHC profiles
for CRT and HMGB-1 showed less robust responses to OX, OX
plus IND (H and L) and OX plus IND-NV (L) (Supplementary
Fig. 7d, f). Likewise, assessment of TLR4 expression by IHC or
flow cytometry analysis of CD45+/CD11b+/CD11c+ cells con-
firmed the synergy between OX and IND-NV (H and L)
(Supplementary Fig. 7g). Local OX plus IND-NV (H) adminis-
tration was also accompanied by significant IFN-γ release, in
parallel with increased staining for CC-3 (Supplementary Fig. 7h,
j). This was accomplished by decreased abundance of the anti-
inflammatory cytokine, IL-10, which contributes to immune
suppression (Supplementary Fig. 7i). All considered, these data
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confirm that, in addition to the impact on the adaptive immune
system, the combination of free OX plus IND-NV has unique
stimulatory effects on the innate immune system.
Development of a dual delivery carrier for OX plus IND-PL.
An IV injectable carrier was established for dual delivery of OX
plus IND in the orthotopic KPC model, which closely mimics the
growth and metastatic profile of human PDAC29–31. We chose a
lipid bilayer (LB) coated MSNP platform based on drug loading
capacity, stability, and effective biodistribution to orthotopic
PDAC sites by a transcytosis mechanism4, 32. The MSNP plat-
form has been used extensively for the drug delivery in cancer
therapy4, 5, 32–37. The increased ability of a supported LB over
that of nanovesicles constituted another reason for the choice of
MSNPs. Moreover, the LB can also be used to incorporate IND-
PL, while serving at the same time to encapsulate OX in the
porous interior (Fig. 5a). Optimal design of the LB was accom-
plished by employing an IND-PL/Cholesterol/DSPE-PEG2K
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mixture at a molar ratio of 75:20:5 (Supplementary Fig. 8a). The
biofilm was laid down at the bottom of a round bottom flask, to
which the OX-soaked MSNPs were added, followed by sonica-
tion, particle purification and washing4, 5. As a control, we syn-
thesized a MSNP in which OX was encapsulated in an IND-PL
free carrier (OX/LB-MSNP). CryoEM images of the dual-delivery
(Fig. 5a and Supplementary Fig. 8c) and OX/LB-MSNP (Sup-
plementary Fig. 8d) carriers showed particles of ~ 83 nm and ~
82 nm in size, respectively. The particles are uniformly coated
with an intact LB, ~ 6.5 nm thick, and slight-negative zeta
potential. The OX loading capacities for OX/LB-MSNP and OX/
IND-MSNP were 4.5% and 4.4%, respectively (Supplementary
Fig. 8c, d). The particles had good colloidal stability in biological
media for up to 30 days (Supplementary Fig. 8b).
To visualize the biodistribution of the IV-injected OX/IND-
MSNP, 0.1% w/w Dylight 680-labeled DMPE was incorporated
into the lipid biofilm. This allowed IVIS imaging of the near-
infrared (NIR) labeled particles at the orthotopic tumor site, as
early as 2.5 h (Fig. 5b, upper panel). Particles were retained at the
tumor site for up to 48 h, and could also be observed in the
explanted organs, obtained from euthanized animals (Fig. 5b,
lower panel). The ex vivo images also showed biodistribution to
the liver and spleen, independent from the tumor site. The PK of
OX and IND were assessed using WinNonlin software after
tumor-bearing mice were IV injected with the OX/IND-MSNP
carrier (5 mg/kg OX, 50 mg/kg IND) (Fig. 5c). Blood was
collected at the indicated time points (0.083, 2, 8, 24 and 48 h)
to measure OX, IND and silicon (Si) concentrations. The 1st
measurement at 5 min (0.083 h) represents Cmax. Animals were
euthanized at 48 h to assess the IND content of the collected
organs by UPLC-MS/MS (Fig. 5d). Compared to free OX, lipid-
coated MSNP encapsulation significantly prolonged the circula-
tory t1/2 of this drug from <0.083 h to 10.4 h (Fig. 5c, left panel).
The t1/2 of IND was 9.5 h, which is significantly longer than the t1/
2 <0.083 h for free IND (Fig. 5c, right panel, Supplementary
Fig. 4i). These results agree with calculation of t1/2 for Si, which
was determined to be 9.2 h (Supplementary Fig. 9). Calculated as
a % of the total injected dose, ∼4 wt% of OX and IND could be
seen to distribute to the tumor site by 48 h (Fig. 5d). The % ID at
the tumor site is in line with data obtained for FDA-approved
nanoparticles such as Abraxane (~ 2.4%)38, Doxil (~ 3%)39, 40,
and Onivyde (~ 2%)41.
Effective anti-PDAC immunity by a dual delivery carrier.
Following orthotopic implantation of luciferase-expressing KPC
cells in the pancreas of B6/129 mice, the animals were IV injected
with the OX/IND-MSNP carrier on days 10, 14, 18, and 22
(Fig. 6a). Each animal received a MSNP dose of 111 mg/kg
(equivalent 5 mg/kg OX and 50 mg/kg IND per injection). The
controls included mice receiving saline, free OX, OX/LB-MSNP
(without IND-PL), IND-NV only, or IND-NV plus free OX at
equivalent doses. Monitoring of orthotopic tumor growth by IVIS
imaging and calculating luminescence intensity (Fig. 6b)
demonstrated significantly higher rates of tumor shrinkage for
OX/IND-MSNP treatment compared to controls, including OX/
LB-MSNP. Autopsies were performed to allow ex vivo IVIS
imaging of the primary tumor site, surrounding organs and
metastatic sites (Fig. 6c). The imaging data were confirmed by
visual inspection during autopsy (Fig. 6c). This established highly
significant reduction in the primary tumor size and metastatic
spread during dual-delivery treatment or administration of OX/
LB-MSNP (Supplementary Fig. 10a, b). The rest of the controls
showed large primary tumors and numerous metastatic foci.
Kaplan–Meier plots confirmed that while OX/LB-MSNP
improved survival, the dual-delivery carrier had a significant
survival benefit (Fig. 6d). Additional assessment of innate and
adaptive immune features was carried out using IHC staining
and multi-parameter flow cytometry. Assessment of CD8, Foxp3,
CRT, CD91, HMGB-1, TLR4, IL-12p70, IFN-γ, perforin, IL-10
and CC-3 expression confirmed the observations of the IT
injection model (Fig. 6e, Supplementary Fig. 11a–k). This con-
firms that the dual-delivery carrier was capable of inducing a
cytotoxic T cell response, disappearance of Tregs and induction of
innate immunity. The CD8+/Foxp3+ ratio improved further in
response to OX/IND-MSNP carrier, demonstrating the unex-
pected synergy that can be achieved by dual drug delivery
(Fig. 6e). Assessment of mature CD11c+/CD80+/CD86+ DCs
amounted to ~ 32.4% in animals treated with the OX/IND-
MSNP, which is significantly higher than animals treated with
saline (3.4%), free OX (4.9%), OX/LB-MSNP (17.8%), IND-NV
(5.4%), and IND-NV + free OX (7.2%). We also observed an
increase in CD103 expression in CD45+/CD11b+/CD11c+ cells by
dual drug delivery (Supplementary Fig. 11l); these DCs are par-
ticularly adapted for instructing CD8+ T cell development and
antitumor immunity42, 43.
On the basis of the critical role of CD8-mediated cytotoxicity
and the role of CD91 and TLR4 in the innate immunity (Fig. 4,
Supplementary Fig. 7), we asked, as an extension of the results in
Fig. 6b, whether IV injection of antibodies to CD8 and TLR444 or
an injectable pool of siRNAs targeting CD9145, could interfere
with the protective immune response observed in this experi-
ment45 (Supplementary Fig. 12). Notably, these treatments had a
significant inhibitory effect on the ability of OX/IND-MSNP to
shrink tumor growth, prolong survival, or ability to increase the
CD8+/Tregs ratio (Supplementary Fig. 12a–d). This was also
reflected by IHC staining and the flow cytometry results
(Supplementary Fig. 11a–l).
The dual-delivery particle was well-tolerated in animal safety
studies, without evidence of weight loss, increased liver enzymes
(Supplementary Fig. 13) and interference in organ histology. In
contrast, free OX increased AST, ALT, and ALP levels.
To validate the involvement of the IDO metabolic pathway in
the antitumor response, the collected tumor tissue was used to
analyze the expression of P-S6K and IL-6 mRNA. P-S6K was
significantly upregulated with decreased IL-6 levels in tumors
from OX/IND-MSNP-treated animals (Fig. 6f). These data agree
with the in vitro results (Fig. 3e and Supplementary Fig. 6c).
Immuno-PET imaging confirms anti-PDAC immunity.
Immuno-positron emission tomography (immuno-PET) has
been extensively employed in pre-clinical and clinical studies to
noninvasively and quantitatively track the presence and abun-
dance of CD8+ and other immune cell subsets following immu-
notherapy46–48. This technique is potentially useful to assess
immunotherapy success before the treatment impact at the tumor
site can be determined. To validate tumor-infiltration and sys-
temic activation of CD8+ T cells, a 89Zr-desferrioxamine-labeled
anti-CD8 cys-diabody (89Zr-malDFO-169 cDb) was used for
monitoring. This PET probe has high specificity for tracking
newly-induced CD8+ T cell responses48, 49. We asked whether
PET imaging could show the induction of an effective anti-PDAC
immune response in live animals, IV injected with saline, OX/LB-
MSNP (5 mg/kg OX) or OX/IND-MSNP (5 mg/kg OX and 50
mg/kg IND). Treatment was administered to the animals (n= 3)
on days 10, 14, 18, and 22 after orthotopic implantation. The
89Zr-probe (29–63 µCi) was IV injected on day 26 and microPET
and CT scans were obtained, using a G8 PET/CT scanner (Sofie
Biosciences), at 20 h. Coronal and transverse (Fig. 7a) view signal
analysis for the localization of CD8+ T cells were obtained by
AMIDE software. This demonstrated background levels of CD8+
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T cells in a peripheral distribution in the tumors of saline-treated
animals, accompanied by faint signals in the spleen and tumor
draining lymph node (TDLN) (Fig. 7a, right panel). Since the
PET probe is eliminated renally, the kidneys show intense
radioactivity48. OX/LB-MSNP treatment was associated with a
modest increases in radioactivity in the interior and peripheral
tumor tissues, amounting to 2.5- and 3.1-fold increases, respec-
tively (Fig. 7b). This was accompanied by increased radioactivity
in the spleen and TDLN (Fig. 7a, Supplementary Fig. 14). In
contrast, treatment with OX/IND-MSNP was accompanied by a
prominent increase in the signal intensity in both the peripheral
(7.5-fold) and interior (6.2-fold) tumor regions compared to
saline. There was also a remarkable increase in signal intensity in
the spleen and TDLN. All considered, immuno-PET confirms the
generation of an effective systemic anti-PDAC immune response
based on the synergistic effect of OX and IND-PL delivery.
Discussion
PDAC is an often-fatal and treatment-resistant disease, in des-
perate need of new treatment approaches. We demonstrate three
treatment modalities using ICD to generate an anti-PDAC
immune response. The 1st is a subcutaneous vaccination
approach, which utilizes ex vivo induction of ICD by OX in a
KPC cells to generate a systemic immune response that can
interfere with tumor growth at a remote site, as well as allowing
adoptive transfer to non-immune animals. The 2nd treatment
modality involved local injection of OX plus an IND-PL nano-
vesicle to induce the recruitment of cytotoxic CD8+ T lympho-
cytes, depletion of Tregs, reversal of the CD8+/Foxp3+ ratio,
cytotoxic tumor killing, and tumor shrinkage at the local injection
site. These adaptive immune responses were accompanied by
boosting of the innate immune system, as reflected by CRT and
HMGB-1 expression, as well as the activation of DC population.
The 3rd treatment approach combined OX and IND-PL into a
single MSNP-based nanocarrier, which allows systemic biodis-
tribution and drug delivery to orthotopic KPC tumor sites. The
dual-delivery approach achieved a synergistic anti-PDAC
immune response, associated with a significant increase in ani-
mal survival. Strikingly, IND co-delivery had a significant impact
on the ICD response, in addition to interference in the IDO
pathway.
Our proposed nano-enabled approach for initiating immu-
notherapy offers distinct advantages over current immunotherapy
strategies for PDAC, including peptide and protein vaccines50,
whole-cell vaccination approaches26, DC vaccines51, micro-
organisms52 and immune checkpoint blockade (e.g., anti-CTLA-4
or anti-PD1 or monoclonal antibodies)26. Since most of these
approaches rely on select antigens, the limited scope of the
response fails to reflect the multitude of tumor antigens that may
evolve during immune editing by the tumor. Moreover, the
restricted display of antigenic epitopes to the T-cell antigen
receptor (TCR) may not allow selection of receptors with optimal
affinity or on/off binding constants for an effective response53. In
contrast, ICD facilitates APC uptake and presentation of a full
complement of tumor-associated antigens (mutagenic and non-
mutagenic), which can effectively select the most effective TCRs,
which are capable through receptor proofreading to provide the
most effective instruction for cytotoxic killing. ICD could also
allow the cognitive immune system to adapt to the array of
continuously evolving tumor antigens rather than restricting the
immune response only to the neo-antigens that are putatively
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Fig. 7 Immuno-PET imaging to demonstrate the induction of the systemic immune response by OX/IND-MSNP administration to animals carrying
orthotopic KPC tumors. a Animals with established orthotopic tumors (n= 3/group) were IV injected with saline, OX/LB-MSNP (5mg/kg OX), and OX/
IND-MSNP (5mg/kg OX and 50mg/kg IND on days 10, 14, 18, and 22 post KPC cell implantation into the pancreas. At day 26, 100 µL doses containing
1.07–2.33 MBq (29–63 µCi, 2.3–5.3 µCi/µg)89Zr radiolabeled cDb in saline was IV injected to the same animals. 20 h later, microPET and CT scans were
acquired by a G8 PET/CT scanner (Sofie Biosciences). Coronal (left panel) and transverse views (right panel) were acquired and analyzed by AMIDE
software. OX/IND-MSNP-treated mice showed significantly increased radioactivity in the tumor, spleen, and TDLN, corresponding to the induction and
infiltration of CD8+ T cells. b To evaluate the CD8+ signal at the tumor site, the operator-defined ROIs were used to demonstrate a 6.2- and 7.5-fold
increase in the signal intensity in the tumor interior and periphery, respectively, during OX/IND-MSNP compared to saline treatment. The results are
expressed as mean± SEM. *p< 0.05; **p< 0.01, (ANOVA)
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required for the tumor immune response to checkpoint
inhibitors.
The potential utility of ICD in an anti-PDAC immune
response is reflected in studies using the whole-cell vaccine,
Algenpantucel-L26. This vaccine is comprised of irradiated PDAC
cells, genetically engineered to express the murine enzyme, α (1,
3)-galactosyltransferase (αGT)26. The expression of natural anti-
bodies to αGal in the human host induces a hyper-acute immune
response during vaccination with the PDAC cell lines. Their
death is accompanied by ICD features6, 15. However, while the
data from a phase II vaccine trial have demonstrated an antibody
response to CRT and improved survival in PDAC patients, the
outcome could not be reproduced in a phase III clinical trial54.
This could be due to the limited range and short duration of
tumor antigen presentation by the dying PDAC cells. In addition
to PDAC, good experimental data have been provided to show
the feasibility of ICD-inducing chemotherapy in lung or colon
carcinoma, including further response amplification by immune
checkpoint blockers44, 54. For colon cancer it has also been
demonstrated that core-shell nanoparticles, comprised of an OX
core and a photosensitizing pyrolipid shell conjugate, can
synergize in delivering an abscopal effect55.
This is the 1st report demonstrating the use of an ICD
approach in PDAC through the use of nanocarriers. We also
demonstrate the novelty of using a nanocarrier to generate a
synergistic immune response by co-delivery of an ICD stimulus
and interfering in immune suppression. The timeliness of using
nanocarriers for dual drug delivery is confirmed by recent FDA
approval of VYXEOS™, which provides synergistic daunorubicin
and cytarabine co-delivery to patients suffering from acute
myeloid leukemia56. The practical utility of our platform for
initiating a synergistic immune response in PDAC is supported
by the widespread use of OX as an ingredient of the FOLFIR-
INOX regimen. IND is also being used in PDAC clinical trials as a
chemotherapy adjuvant.
Immune activation in the PDAC microenvironment has to
overcome a number of immune suppressive mechanisms,
including the presence of CD4+/Foxp3+ Tregs, secretion of anti-
inflammatory cytokines, expression of checkpoint inhibitors and
overproduction of IDO. While our results indicate that OX alone
is capable of increasing the CD8+/Foxp3+ ratio at local and sys-
temic tumor sites, the co-administration of a PL-conjugated IDO
inhibitor, IND-PL, significantly enhanced the response para-
meter. This change reflects the importance of the IDO metabolic
pathway in tumor immune surveillance, in much the same way as
the regional IDO expression in the placenta plays a role in pro-
tecting the fetus18. Importantly, the delivery of IND in the form
of a prodrug also impacts the innate immune system, as
demonstrated by enhanced expression of CRT and HMGB-1 by
the dual delivery carrier (Supplementary Figs. 7d, f, and 11c, e).
This could reflect the effect of IND in promoting autophagy as a
result of activation of the mTOR1 pathway. Autophagy plays a
key role in ATP release during ICD21.
IDO inhibitors are currently undergoing clinical trials in sev-
eral cancer types, including breast, prostate, melanoma, brain and
pancreas24. This includes the use of IND together with gemcita-
bine, nab-PTX and anti-PDL124. However, we have not observed
ICD induction by gemcitabine or PTX in pancreatic cancer cell
lines. A major advantage of our nanocarrier approach is the
improvement of the PK and intratumoral concentration of IND-
PL, along with OX. Free IND is relatively water insoluble and has
unfavorable PK characteristics. In contrast, IND-NV significantly
increased the uptake and release of IND in tumor cells (Fig. 3c);
this also translated to a more robust interference in IDO-
mediated immune suppressive signaling pathways at the tumor
site (Figs. 3e, 6f, and Supplementary Fig. 6c). In addition to
improving the circulatory t1/2 and PK of IND, the dual delivery
carrier also improved the PK of OX (Fig. 5c and Supplementary
Fig. 4i). Harmonization of their PKs contributed to synergy at the
tumor site.
How can this discovery be translated to the clinic? On the basis
of our animal studies, possible ways to improve immunotherapy
in patients could include the following: (i) tumor cell collection
from resected cancer tissues during surgery, with the possibility of
developing a culture-based vaccine approach; (ii) local injection
of OX and IND-PL into the tumor under remote guidance,
during collection of biopsies or direct visualization during sur-
gery; (iii) systemic administration of one or a combination of
treatment modalities, which may include the use of free drugs,
IND-NV or the dual-delivery carrier. In addition, it is also pos-
sible to enhance treatment efficacy by nanomaterials that exhibit
catalytic properties that can be used for sequential induction of
ER stress, ICD, autophagy and the release of adjuvants. It is also
possible to use nanocarriers to deliver other FDA-approved drugs
(e.g., cardiac glycosides, Ca2+-activated K-channel agonists, etc)57
to achieve ICD, individually or in combination with che-
motherapy or ICD-inducing nanoparticles. Another approach
could be to combine chemotherapy and IND delivering nano-
particles with immune checkpoint blockers, irradiation, photo-
dynamic therapy, or cytotoxic viruses to achieve additional
immune response amplification. The ultimate goal of a cure of
PDAC through immunotherapy will likely require a series of
steps and combination therapies.
In summary, we demonstrate that a nano-enabled approach for
OX and IND delivery to the PDAC site can be used for a
synergistic immunotherapy response premised on the induction
of ICD plus reversal of IDO immune suppressive effects. The
nano-enabled approach can be reduced to clinical practice by
using a vaccination approach, local treatment or systemic
administration. The same approach may also apply to other
cancers.
Methods
Cells and mice. A KPC cell line, derived from a spontaneous tumor in a transgenic
KrasLSL-G12D/+/ Trp53LSL-R172H/+/Pdx-1-Cre mouse, was used for the cellular
studies and growing subcutaneous and orthotopic tumors in mice25. It was not
logistically feasible to use the spontaneous mouse model because of the variability
of tumor development, making it impossible to obtain enough mice for a com-
prehensive study. We also obtained a PANC-1 cell line from ATCC. Both cell lines
were cultured in complete DMEM medium, containing 10% FBS, 100 U/mL
penicillin, 100 μg/mL streptomycin, and 2 mM L-glutamine. All cell lines were
tested to ensure freedom from mycoplasma contamination. To visualize KPC
tumor growth by IVIS bioluminescence imaging, the KPC cells were stably
transfected with a luciferase-expressing lentiviral vector in the vector core facility at
UCLA4. Female B6/129 mice (Jackson Laboratory, 8~ 10 weeks old) were used to
grow subcutaneous or orthotopic KPC tumors. The animals were maintained
under pathogen-free conditions and all animal experiments were approved by the
UCLA Animal Research Committee.
CRT expression and HMGB-1 release from the cell lines. 1 × 105 KPC or
PANC-1 cells were seeded in 24-well plates overnight. The cell culture medium was
removed and replenished with Cis, OX and DOX containing media at the indicated
concentrations for 4 h or 24 h. Supernatants were collected for HMGB-1 detection
by an ELISA kit (IBL International GmbH), according to the manufacturer’s
instructions. To assess CRT expression by flow cytometry, cells were trypzinized,
washed in cold PBS and then sequentially stained with a primary rabbit anti-CRT
antibody (Ab2907, Abcam), followed by an Alexa Fluor® 680-conjugated goat-anti-
rabbit IgG antibody for 30 min at 4 °C. The cells were incubated in 500 µL PBS
containing 50 µg/mL propodium iodide before washing and assessment in a LSRII
flow cytometer (BD Biosciences). The data were expressed as fold-increase in mean
fluorescence intensity (MFI) compared to the PBS control. The analysis was
repeated once. Visualization of CRT expression was performed in KPC cells added
to 8-well chamber slides (Lab-Tek®). Each well contained 1 × 104 KPC cells in 0.4
mL of culture medium. After incubation with 50 µM Cis, 50 µM OX, and 1 µM
DOX for 4 h, cells were fixed and washed 3 times. Cells were stained with an Alexa
Fluor® 647-conjugated anti-CRT antibody (ab196159, 1/500, Abcam) for 30 min,
followed by co-staining with 5 μg/mL Alexa Fluor® 488-conjugated wheat germ
agglutinin (WGA) to visualize the cell surface membrane. Slides were mounted
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with Hoechst 33,342 nuclear dye and visualized under a Leica SP8-SMD confocal
microscope. High magnification images were obtained under the 63 × objective
lens.
Vaccination approach to induce systemic immunity. The timeline for the vac-
cination schedule is described in Fig. 2c. KPC cells were exposed to PBS, 100 µM
Cis, 50 μM OX and 1 μM DOX for 24 h to induce CRT expression. After con-
firmation of CRT expression by flow cytometry, 1 × 106 dying cells were injected
twice into the right flank of B16/129 mice (n= 7), 7 days apart. 14 days after the 1st
injection, the animals received SC injection of viable KPC cell suspensions (1 × 106
cells in 0.1 mL DMEM/matrigel, 1/1, v/v) in the contralateral (left) flank. Tumor
size was measured by a digital caliper every 3–4 days, and the volume calculated
according to the formula π/6 × length × width2. Tumor burden was also monitored
by IVIS imaging on day 7, 18, 25, and 29 and quantitatively expressed as lumi-
nescence signal intensity in the region of interest (ROI). The data were present as
“spaghetti plots” that display the tumor growth in each individual animal. Statis-
tical comparison of the groups was performed using two-way analysis of variance
with SPSS software. Animals were killed on day 29 and the tumors were collected
for flow cytometry and IHC analysis as described below.
Orthotopic rechallange and adoptive transfer. In order to demonstrate immune
memory, surviving mice from the vaccination study were used for this experiment.
Three tumor-free survivors in the OX group and 3 healthy mice were used for
secondary tumor challenge by orthotopic pancreatic implant on day 74. This was
accomplished by injecting 1 × 106 live KPC-luc cells into the pancreas after minor
surgery4. Tumor development was monitored by IVIS imaging. While the healthy
animals developed pancreatic tumors, the animals in the OX-treated group
remained tumor-free. After killing of the survivors and collecting their splenocytes
on day 132, adoptive transfer was performed to non-immune B16/129 recipients
(n= 6). This was accomplished by injecting 3 × 106 splenocytes IV. The controls
consisted of 6 non-immunized animals injected with splenocytes from non-
immune animals or 6 animals injected with splenocytes from saline-treated ani-
mals. Two days later, each of the groups was challenged by injection of 2 × 105
viable KPC cells SC. To confirm the tumor specificity, 3 identical injected animal
groups were used for SC challenge with B16 melanoma cells.
Synthesis of the IND-PL prodrug. The procedure was carried out in 3 steps, the
1st of which was “synthesis of Boc-IND”. IND (200 mg), Di-tert-butyl dicarbonate
(Boc anhydride, 260 mg) and NaHCO3 (230 mg) were dissolved in a mixture
containing 10 mL tetrahydrofuran (THF) and 10 mL H2O. The sample was stirred
at 0 °C for 15 min and then at room temperature overnight. THF was removed by
evaporation, followed by the addition of 1 N HCl (10 mL). The solution was
brought to pH= 1 by crystal precipitation, followed by suction filtration to purify
the pale-yellow solid. The molar ratio of the product vs. starting materials was used
to determine the yield in each step (Supplementary Fig. 4a). Synthesis success was
confirmed by 1H-NMR, 14C-NMR and ESI-MS (positive mode), as described
online. Subsequent synthesis of Boc-IND-PL was performed by dissolving 100 mg
1-palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine (PL), 150 mg Boc-IND,
156.7 mg EDC, 97.3 mg DMAP, and 146 mg DIPEA in water-free dichloromethane
(DCM, 20 mL), while stirring for 48 h. The resulting pale-yellow solution was
obtained by funnel separation (repeated 3 times, using water). The DCM solution
was vacuum-dried and purified by silica-gel chromatography, using a mobile phase
comprised of ethanol:chloroform:water (4:6:1, v/v/v). Analysis of the yield, and
characterization of the product was performed by NMRs and ESI-MS, as described
online (Supplementary Fig. 4). In the final step, the synthesis of IND-PL was
carried out by stirring 58.6 mg Boc-IND-PL in a mixture of 1 mL trifluoroacetic
acid and 1 mL DCM for 6 h at room temperature. The solvent was removed by
rotatory evaporation and the residue was re-dissolved in 400 µL DCM, to which 25
mL diethyl ether was added dropwise, followed by centrifugation to retrieve the
pale-yellow solid. The washing step was repeated thrice using diethyl ether. The
final product was comprehensively characterized for its purity and composition by
NMRs and ESI-MS.
Self-assembly of IND-PL into INV-NV nanovesicles. The self-assembly of IND-
PL into IND-NV was carried out by a slight variation of a liposome synthesis
procedure. Briefly, 5 mg of IND-PL was dissolved in chloroform in a 50 mL round
bottom glass flask. The solvent was evaporated under a rotatory vacuum to form a
thin film, which was dried further under vacuum overnight. The film was hydrated
with 1 mL of PBS and sonicated for 1 h. To obtain size-controlled IND-NV
assembly, the suspension was extruded 13 times through a Mini-Extruder (Avanti
Polar Lipids), using a polycarbonate membrane with 100 nm pores (Avanti Polar
Lipids) at 80 °C. IND-NV size and morphology were assessed by dynamic light
scattering and cryoEM, respectively (Fig. 3b).
Cellular uptake of IND-NV. KPC cells were treated with free IND or IND-NV at
the IND dose-equivalent of 100 µg/mL for 4, 24, and 72 h, respectively. This dosing
is based on literature.20 The cells were detached by trypsinization and extracted
overnight in methanol to determine drug content by UPLC-MS/MS analysis. These
extracts were added to a C18 Column (130 Å, 1.7 µm, 2.1 mm × 50 mm), connected
to Waters LCT Premier with ACQUITY UPLC and Auto sampler. The separation
involved gradient elution as follows: (i) 0–4.5 min, 95% water + 5% Acetonitrile; (ii)
4.5–6 min, 5% water + 95% Acetonitrile; and (iii) 6–10 min, 95% water + 5%
Acetonitrile. The flow rate was 0.4 L/min. Since IND is a small molecule that may
diffuse from trypsinized cells, with the possibility of impacting intracellular drug
analysis, we also performed the experiment by washing the pre-chilled monolayer
with ice-cold buffer and then extracting in situ before UPLC-MS/MS analysis.
Effect of IND-NVs on immunoregulatory signaling pathways. 1 × 106 KPC cells
were seeded into each well of a 6-well plate overnight, using Trp-deficient DMEM
(Gibco)21. After attachment, the cells were treated with IND or IND-NV at the
indicated concentrations for 3 h. The supernatants were collected to assess IL-6
levels by an ELISA kit (BD Biosciences) according to the manufacturer’s instruc-
tions. In order to determine the abundance of P-S6, total S6K and GAPDH by
western blotting, cells were extracted in a lysis buffer, followed by electrophoresis
on a 4–12% SDS-PAGE gel (Invitrogen, Grand Island, NY). The proteins were
subsequently transferred to a PVDF membrane. After blocking in 5% BSA, the
membrane was sequentially overlaid with primary and secondary antibodies and
the blots developed by the addition of the ECL solution. The original uncropped
scans of the blot was shown in Supplementary Fig. 5e. The band intensity on the
film was quantified by Image J software.
Local tumor injection of free OX plus IND-NV. 1 × 106 KPC cells (in 100 µL
DMEM/matrigel, 1/1, v/v) were SC injected in the right flank of the animals (n =
7). The dose design is based on literature15. When tumors reached 60–80 mm3 in
size, the mice received one-time IT administration of saline, free OX (1.25 mg/kg),
free OX (1.25 mg/kg) + free IND (2.5 mg IND/kg), free OX (1.25 mg/kg) + free IND
(12.5 mg/kg IND), free OX (1.25 mg/kg) + IND-NV (2.5 mg/kg IND) and free OX
(1.25 mg/kg) + IND-NV (12.5 mg IND/kg). We also included a single IT injection
of free IND (12.5 mg IND/kg) and IND-NV (12.5 mg IND/kg) as additional
controls. Tumor burden was measured by a digital caliper, similar to what was
described in the vaccination experiment. On day 31, tumors were collected for flow
cytometry and IHC analysis as described above.
Synthesis of the OX/IND-MSNP nanocarrier. An OX/IND-MSNP dual-delivery
carrier was designed by trapping OX in the mesoporous interior of a ~ 70 nm
MSNP, using a lipid bilayer into which IND-PL was incorporated. Particle coating
used a biofilm method that rapidly encapsulates the MSNP core during energy
input4, 5. This was accomplished by adding the OX-soaked MSNP suspension on
top of a lipid biofilm. For OX loading into the pores of MSNP, 30 mg of OX was
dissolved in 30 mg of a MSNP solution (4 mL) while stirring overnight. The
mixture was centrifuged at 15000 rpm 3 times for 15 min to remove the non-
encapsulated OX and then resuspended in 3 mL DI water. The biofilm was com-
prised of a 60 mg lipid mixture, which included IND-PL, cholesterol, and DSPE-
PEG2K in the molar ratio of 75:20:5. This ratio was derived by experimenting with
different lipid mixtures (Supplementary Fig. 8a). The lipids were dissolved in
chloroform at a concentration of 20 mg/ml, and added to a round bottom flask.
Following rotary vacuum evaporation of the chloroform, the OX-soaked MSNP
suspension was added to the uniformly dispersed lipid biofilm, and then sonicated
with a probe sonicator for 1 h, using a 15/15 s on/off working cycle at a power
output of 32.5W. Then drug-loaded particles were washed 3 times by cen-
trifugation at 15,000 rpm for 15 min to remove free liposomes, and resuspended in
DI water, saline, or PBS, as indicated. The purified OX/IND-MSNPs were fully
characterized for size, charge, loading capacity, morphology and endotoxin level
using DLS, UPLC-MS/MS, ICP-OES, cryoEM and the Chromogenic LAL Assay,
respectively. An optimal particle batch was comprised of particles with size around
100 nm, slightly negative charge and suspension stability of at least one month.
Control particles were synthesized by entrapping OX only inside the particle with a
lipid bilayer of the same composition, except for using DSPC in place of IND-PL to
yield OX/LB-MSNP (DSPC/cholesterol/DSPE-PEG2K= 75:20:5, molar ratio in
lipid bilayer). Particles were stored at 4 °C prior to use in cellular and animal
experiments.
PK study of IV-injected OX/IND-MSNP. Orthotopic tumor-bearing mice were
used in this experiment (n= 6). To visualize OX/IND-MSNP nanoparticle bio-
distribution in vivo, NIR-labeled OX/IND-MSNP was prepared by incorporating
0.1% w/w Dylight 680-labeled DMPE in the lipid biofilm4. For IVIS biolumines-
cence imaging of the tumor site, mice were injected intraperitoneally (IP) with 75
mg/kg D-Luciferin. Reference fluorescence images for the tumor-bearing mice were
acquired prior to particle injection (0 h). Following a single IV injection of NIR-
labeled OX/IND-MSNP, delivering the equivalent of 5 mg/kg OX and 50mg/kg
IND, mice were imaged at 2.5, 8, 24, and 48 h post injection. After killing, ex vivo
images were obtained for the collected tumor, heart, liver, spleen, kidney, and lung
tissues at 24 h and 48 h. In a separate experiment, OX/IND-MSNP (5 mg/kg OX;
50 mg/kg IND) was IV administered to orthotopic KPC tumor-bearing mice (n =
6). Free OX served as a control. At the indicated time points (0.083, 2, 8, 24, and 48
h) plasma was collected and digested in methanol or HNO3/H2O2 for UPLC-MS/
MS (to measure IND&IND-PL) or to perform ICP-OES (for Si elemental analysis),
respectively. The use of 5 times reflect the limitation of not withdrawing a total of
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>250 µL blood and requirement of 50 µL for each assay. The t1/2 was calculated
based on a non-compartmental model, using WinNolin software58–60. The col-
lected tumor tissue and organs were also used to measure the drug and Si contents
using similar methods.
Efficacy assessment of the dual delivery OX/IND-MSNP carrier. We utilized a
National Cancer Institute protocol44, 61 to calculate the maximum tolerated dose
(MTD) of IV-injected free and encapsulated OX; this was determined to be 8 and
12 mg/kg, respectively. Briefly, two healthy male b6/129 mice were IV injected with
a 2.5 mg/kg (C1 dose) equivalent of free or encapsulated OX. This was followed by
a dose escalation factor of 1.8 to obtain the Cn dose, which is followed by animal
death within 24 h after the last administration. The second round dose-seeking
began with the Cn−1 dose and utilized a 1.15 escalation factor (n= 2) to determine
the MTD, which is defined as the absence of mortality or morbidity. The MTD was
validated by injecting six mice, which were monitored for 15 days to evaluate the
absence of morbidity, mortality, or >15% weight loss. The corresponding MTD
value for IV-injected IND-NV was >500 mg/kg. Orthotopic tumor-bearing B6/129
mice (n= 7) were randomly assigned to 9 groups, each including seven animals.
The mice were IV injected with OX/IND-MSNP to deliver a dose of 5 mg/kg OX
and 50mg/kg IND every 4 days from day 10 onwards. The controls included
equivalent doses of free OX, OX-laden particles only, IND-NV, IND-NV + free
OX, delivered at the same administration frequency. We also included saline as a
negative control. Tumor burden was monitored by IVIS imaging from day 10
onwards, allowing the bioluminescence imaging intensity to be quantitatively
expressed in the operator-defined ROI. The tumor tissue and major organs were
collected for quantification of ex vivo bioluminescence image intensity. On day 36,
tumors were collected for flow cytometry, IHC analysis and determination of
mRNA expression (for P-S6K, AHR, and IL-6) by real-time PCR. We also with-
drew blood for blood chemistry analysis. In order to assess the adaptive and innate
immune changes leading to effective anti-PDAC immunity during OX/IND-MSNP
treatment, we also asked whether dosing with anti-CD8 and anti-TLR4 antibodies
or knockdown of CD91 by siRNA could change the outcome (Supplementary
Fig. 12). The experiment was repeated once, using the same treatment compar-
isons, to determine the effect on survival rate in each group (n= 7). Kaplan–Meier
plots were used to express animal survival.
Immunohistochemistry analysis. In order to visualize the phenotypic changes
during the induction of innate and cognate immune response, IHC analysis was
performed. Tumors collected from the killed animals were evenly divided into two
parts, one for IHC and the other for flow cytometry. To prepare the tumor samples
for IHC staining, the tumor pieces were fixed in 10% formalin followed by paraffin
embedding. Tumor sections of 4 μm thickness were mounted on glass slides by the
UCLA Jonsson Comprehensive Cancer Center Translational Pathology Core
Laboratory for hematoxylin-eosin (H&E) staining as well as a series of IHC
staining procedures, following standardized protocols. Briefly, the slides were
deparaffinized, incubated in 3% methanol-hydrogen peroxide, followed by 10 mM
EDTA (pH= 8) or 1 mM sodium citrate (pH = 6) at 95 °C using the Decloaking
NxGen Chamber (Biocare Medical, DC2012). The slides were brought to room
temperature, rinsed in PBST (Phosphate Buffered Saline containing 0.05% Tween-
20) and then incubated with individual primary antibodies for 1 h. The slides were
rinsed with PBST and then incubated with appropriate HRP-conjugated secondary
antibodies at room temperature for 30 min. After rinsing with PBST, the slides
were incubated with DAB (3,3′-Diaminobenzidine) or Vulcan Fast Red Chromo-
gen Kit 2 (for the CRT and CD91/LRP1 protocols only) (Biocare Medical, FR805)
for visualization. Subsequently, the slides were washed in tap water, counterstained
with Harris’ Hematoxylin, dehydrated in ethanol, and mounted with media. The
slides were scanned by an Aperio AT Turbo Digital Pathology Scanner (Leica
Biosystems) and interpreted by an experienced veterinary pathologist.
Antibody sources used for IHC. Primary antibody sources and dilutions (2%
BSA) obtained from Abcam included: anti-CD4 (ab183685, 1/200), anti-CRT
(ab2907, 1/50), anti-HMGB-1 (ab18256, 1/200), anti-LRP1(CD91) (ab92544, 1/50),
anti-TLR4 (ab13867, 1/50), and anti-perforin (ab16074, 1/100). Anti-CD8 (#14-
0808, 1/100), anti-Foxp3 (#13-5773, 1/200) and anti-IL-10 (#14-7101, 1/50) were
from eBioscience. Anti-cleaved caspase-3 antibody was from Cell Signaling (#9664,
1/200) and anti-IFN-gamma from Novus Biologicals (NBP1-19761, 1/200). Anti-
IL-12p70 was purchased from Novus Biologics (NBP1-85564, 1/100), and anti-IDO
was from Biolegend (#122402, 1/100) Secondary antibodies included MACH2
Rabbit HRP-Polymer (Biocare Medical, RHRP520L) for IL-10 and TLR4; MACH2
Rabbit AP-Polymer (Biocare Medical, RALP525) for CD91; Dako EnVision +
System HRP-labeled polymer Anti-Rabbit (Dako, K4003) for the remaining
biomarkers.
Flow cytometry analysis. The tumor pieces obtained for single-cell analysis were
cut into smaller pieces with scissors and digested in DMEM with 0.5 mg/mL col-
lagenase type I (Worthington Biochemical Corporation) at 37 °C for 1 h. The
digested tissues were gently meshed though a 70 μM cell strainer, twice. Red blood
cells were lysed by Ack lysing buffer (Gibco) according to the manufacturer’s
instructions. The single-cell suspensions were washed twice and resuspended in
staining buffer. Following cell counting and aliquoting, the suspensions were
incubated with FcBlock (TruStain fcXTM anti-mouse CD16/32, clone 93, BioLe-
gend) for 20 min to avoid nonspecific binding. Staining was then performed by
using various combinations of fluorophore-conjugated antibodies for 40 min at 4 °
C. The following anti-mouse antibodies were purchased from BD Biosciences:
CD45-V450 (#560501, 1/100), CD45-APC-Cy7 (#557659, 1/100), CD4-Alexa
Fluor488 (#557667, 1/100), Foxp3-PE (#563101, 1/100), CD8α-PE (#561095, 1/
100), CD11b-PE (553311, 1/100), CD11c-V450 (560521, 1/100). CD284 (TLR4)-
APC (145406, 1/100) and CD103-Alexa Fluor 647 (#121410, 1/250) was purchased
from BioLegend. LRP1 (CD91)-Alexa fluor 647 (ab195568, 1/250) was obtained
from Abcam. CD3-APC-eFluor780 (#47-0032-82, 1/100) and CD25-APC (#17-
0251-82, 1/100) were purchased from eBiosciences. Multi-parameter staining was
used to identify the following populations of interest: (i) CD8+ T cells (CD45+CD3
+CD8+CD25+), (ii) Tregs (CD45+CD3+CD4+Foxp3+), (iii) CD91+ DCs (CD45
+CD11b+CD11+cCD91+), (iv) TLR4+ DCs (CD45+CD11b+CD11+cTLR4+), and (v)
CD103+ DCs (CD45+CD11b+CD11+cCD103+). For intracellular Foxp3 staining,
cells were further fixed and permeabilized using a Foxp3/Transcription Factor
Staining Buffer Set (eBioscience). After washing, cells were used for flow cytometry
analysis (machine brand name: LSRII, BD Biosciences). The data were processed by
FlowJo software (Tree Star). Dead cells and doublets were excluded based on
forward and side scatter.
Immuno-PET imaging. Immuno-PET imaging was used to assess systemic
immune activation in live animals., MalDFO-conjugated anti-CD8 cDb fragment
was incubated for 1 h at room temperature at about 4–5 µCi 89Zr per µg protein48,
49. Radiolabeling efficiency was measured by ITLC (Biodex Medical Systems) using
20 mM citrate buffer pH 5.6 as the mobile phase. The ITLC strip was cut in half
and sections were counted using a Wizard 3″ 1480 Automatic Gamma Counter
(Perkin-Elmer). Protein was purified using BioRad6 Spin columns equilibrated
with PBS. Radiochemical purity was assessed by ITLC as above. Nine KPC
orthotopic mice were established as described earlier. Saline, OX/LB-MSNP (5 mg
OX/kg), and OX/IND-MSNP (5 mg OX/kg and 50 mg IND/kg) were IV injected to
mice (n= 3) on day 10, 14, 18, and 22 for 4 consecutive administration post KPC
tumor cells inoculation into pancreas. At day 26, 100 µL doses containing 1.07–2.33
MBq (29–63 µCi, 2.3–5.3 µCi/µg) 89Zr radiolabeled cDb PET probe in saline was IV
injected to orthotopic KPC-tumor-bearing mice. 20 h later, mice were anesthetized
and microPET and microCT scans were acquired using a G8 PET/CT scanner
(Sofie Biosciences) in CNSI. MicroPET images were reconstructed by non-
attenuation or scatter corrected maximum a posteriori (MAP) reconstruction.
Images including coronal and transverse views were acquired and analyzed by
AMIDE (a software for viewing, analyzing, and registering the volumetric PET
imaging data).
Statistical analysis. Statistical analysis was carried out with the SPSS statistical
package (version 23, SPSS). Differences between groups were analyzed using
analysis of variance (ANOVA). Comparison of Kaplan–Meier survival curves was
performed with the Log-rank Mantel–Cox test. The results were expressed as mean
± SEM of at least three independent experiments. Statistical significance thresholds
were set at *p < 0.05; **p< 0.01; #p < 0.001.
Data availability. The data that support the findings of this study are available
within this article and its Supplementary Information or from the corresponding
author upon reasonable request.
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